By blocking these interactions, anti–PD-1, anti–CTLA-4 and anti–PD-L1 immunotherapies promote glycolytic metabolism in tumor-infiltrating T cells and improve their antitumor functions. This evidence concerns the gene CTLA4 and neoplasm.